<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02065076</url>
  </required_header>
  <id_info>
    <org_study_id>13089</org_study_id>
    <nct_id>NCT02065076</nct_id>
  </id_info>
  <brief_title>Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients</brief_title>
  <acronym>SKIP</acronym>
  <official_title>Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Ambulatory Pre-dialysis Outpatients : a Randomized Triple-blind Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maisonneuve-Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nephrology Research Axis of Maisonneuve Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Pharmacy, Maisonneuve Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maisonneuve-Rosemont Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine if sodium polystyrene sulfonate (SPS) is an&#xD;
      effective treatment of mild hyperkalemia in chronic kidney disease patients followed at a&#xD;
      pre-dialysis or nephrology outpatient clinic. Subjects will be randomized to one of two&#xD;
      treatment arms: 30 g of placebo or SPS to be taken orally once daily for seven days. The&#xD;
      change in serum potassium levels will be compared in both treatment groups. The proportion of&#xD;
      subjects attaining normokalemia (3.5 to 5.0 mmol/L) after seven days of treatment will also&#xD;
      be compared. Finally, side effects will be reported for each treatment arm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
      Hyperkalemia affects up to 10% of patients suffering from chronic kidney failure and up to&#xD;
      42% of patients with an estimated glomerular filtration rate lower than 20 mL/min/1.73m2.&#xD;
      There is currently limited evidence on the use of sodium polystyrene sulfonate for the&#xD;
      treatment of mild hyperkalemia. There are even fewer trials supporting its use over several&#xD;
      days. To our knowledge, only one other study has evaluated its chronic use in fourteen&#xD;
      patients, but hadn't controlled for recent changes in medications. Since its use is&#xD;
      associated with adverse events that can considerably affect patients' quality of life, it&#xD;
      appears primordial to better assess its place in the treatment of hyperkalemia in&#xD;
      pre-dialysis patients.&#xD;
&#xD;
      Methods&#xD;
&#xD;
      The aim of this trial is to evaluate the use of sodium polystyrene sulfonate in the treatment&#xD;
      of mild asymptomatic hyperkalemia in predialysis patients. Participants will be randomized to&#xD;
      receive either 30 g of placebo or 30 g of SPS orally once daily for seven days. Serum&#xD;
      potassium levels will be assessed at baseline and on the day following the last dose of their&#xD;
      treatment. The change in serum potassium levels and the proportion of patients attaining&#xD;
      normokalemia will be compared between study groups. The incidence of adverse events (nausea,&#xD;
      diarrhea, constipation, electrolyte disorders) will also be reported. Participants will also&#xD;
      be asked to fill out a food diary for 3 out of the 7 study days. This diary will be used to&#xD;
      estimate each participant's average daily intake of potassium and therefore evaluate the&#xD;
      similarity of diets between both intervention arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum potassium levels from baseline</measure>
    <time_frame>After 7 days</time_frame>
    <description>Compare the change in serum potassium levels from baseline in both treatment arms after 7 days of treatment with SPS or placebo 30 g once daily</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects attaining normokalemia (serum potassium level of 3.5 to 5.0 mmol/L) in each treatment arm</measure>
    <time_frame>After 7 days</time_frame>
    <description>Compare the proportion of subjects attaining normokalemia (serum potassium level of 3.5 to 5.0 mmol/L) in each arm after one week of sodium polystyrene sulfonate or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events in each treatment group</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Report the number of patients with adverse events, notably nausea, diarrhea, constipation, electrolyte disorders (hypomagnesemia, hypernatremia, hypophosphatemia, hypocalcemia, hypokalemia)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Hyperkalemia</condition>
  <condition>Chronic Kidney Failure</condition>
  <arm_group>
    <arm_group_label>Sodium Polystyrene Sulfonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 g sodium polystyrene sulfonate powder, mixed with water qs ad 150 ml, taken PO once daily for seven days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactose with carob gum</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 g placebo powder, mixed with water qs ad 150 ml, taken PO once daily for seven days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium polystyrene sulfonate</intervention_name>
    <arm_group_label>Sodium Polystyrene Sulfonate</arm_group_label>
    <other_name>SPS</other_name>
    <other_name>Kayexalate</other_name>
    <other_name>Solystat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactose with carob gum</intervention_name>
    <arm_group_label>Lactose with carob gum</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years and over&#xD;
&#xD;
          -  Outpatients followed at the pre-dialysis or nephrology clinics of Maisonneuve-Rosemont&#xD;
             Hospital&#xD;
&#xD;
          -  Subjects who have taken SPS in the past 7 days: serum potassium level measured for&#xD;
             their regular followup of 4.5 to 5.5 mmol/L, inclusive, and serum potassium level of&#xD;
             5.0 to 5.9 mmol/L, inclusive, after a one week washout period&#xD;
&#xD;
          -  Subjects who have not taken SPS in the past 7 days: serum potassium levels measured&#xD;
             for their regular followup and on the day of randomisation of 5.0 to 5.9, inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a contraindication to SPS : known hypersensitivity to the product,&#xD;
             history of obstructive bowel disease, patients at high risk of obstructive bowel&#xD;
             disease&#xD;
&#xD;
          -  Subjects unable of giving informed consent&#xD;
&#xD;
          -  Subjects with severe or symptomatic hyperkalemia requiring a treatment&#xD;
&#xD;
          -  Subjects on dialysis (hemodialysis or peritoneal dialysis)&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Subjects who have had a change in the dosage of insulin in the past week, if this&#xD;
             change represents more than 10% of the daily total dose or more than 5 units&#xD;
&#xD;
          -  Subjects who stopped, started or changed the dosage of an angiotensin converting&#xD;
             enzyme inhibitor, an angiotensin II receptor blocker or aliskiren in the past 60 days&#xD;
&#xD;
          -  Subjects who stopped, started or changed the dosage of another medication affecting&#xD;
             serum potassium levels in the past 30 days&#xD;
&#xD;
          -  Subjects who have had an episode of decompensated heart failure in the past 30 days&#xD;
&#xD;
          -  Subjects currently enrolled on another research protocol&#xD;
&#xD;
          -  Subjects who are lactose intolerant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Pichette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maisonneuve-Rosemont Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>February 14, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <last_update_submitted>October 1, 2014</last_update_submitted>
  <last_update_submitted_qc>October 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maisonneuve-Rosemont Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Vincent Pichette</investigator_full_name>
    <investigator_title>M.D., Ph.D., FRCP(C), nephrologist</investigator_title>
  </responsible_party>
  <keyword>Sodium Polystyrene Sulfonate</keyword>
  <keyword>Kayexalate</keyword>
  <keyword>Pre-dialysis</keyword>
  <keyword>Outpatients</keyword>
  <keyword>Hyperkalemia</keyword>
  <keyword>Chronic kidney failure</keyword>
  <keyword>Potassium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hyperkalemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polystyrene sulfonic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

